Did the FDA Approve MOTS-c? What the July 23–24, 2026 Advisory-Committee Vote Actually Did

No, the FDA did not approve MOTS-c. On July 23, 2026 the FDA’s Pharmacy Compounding Advisory Committee — the outside panel that advises the agency, abbreviated PCAC — voted to recommend that MOTS-c be added to the 503A bulks list, which names the ingredients a state-licensed pharmacy may use when compounding for an individual patient.

It was the closest call of the day: 7 in favour, 5 against, with 2 abstentions, meaning only 12 of the members present cast a vote either way. And a recommendation is advice — the panel cannot change the list, FDA may disagree, and formal rulemaking has to run its course first. MOTS-c is an unapproved drug today, exactly as it was before the meeting.

MOTS-c was the only substance of the seven whose evaluated use touched obesity. That makes an unusual contrast available, and it is worth sitting with, because it shows how narrow these decisions actually are.

In the same season that a committee recommended adding MOTS-c to the 503A compounding list, FDA separately proposed not to add semaglutide, tirzepatide and liraglutide to the corresponding 503B list — with the comment period on that proposal extended to July 30, 2026. Three heavily-trialled, FDA-approved obesity drugs were being argued away from a compounding pathway while a compound with no completed outcome trial was being recommended toward one.

These are different lists, different sections of the law and different questions, so this is not a contradiction. But it is a useful corrective to the idea that a favourable vote reflects a judgment about how well something works. It does not. The two proceedings were asking about entirely different things.

MOTS-c is a mitochondrial-derived peptide — encoded in mitochondrial DNA rather than the cell nucleus. Of the seven substances heard across the two days, it is the only one that is endogenous in that sense: a molecule the body produces itself, rather than a synthetic construct or a fragment of a larger protein.

That gives it a different identity profile from the day-one peptides FDA’s chemists objected to, since what the molecule is is not really in dispute. What remains in dispute is what administering more of it does. The evidence base is graded preclinical: no completed human outcome trials, with a Phase 2a in prediabetes underway but unfinished. Registration is not completed evidence, and an ongoing trial is not a result.

MOTS-c is prohibited at all times under the WADA Prohibited List 2026, named under S4.4.1 as an AMPK activator and metabolic modulator. The other prohibited peptides heard that day fall under S2, which covers peptide hormones and growth factors.

The practical point for an athlete is that the section number changes nothing: prohibited at all times means in and out of competition, and a favourable FDA compounding vote does not touch it. The two systems are unrelated, and confirming status through Global DRO before use remains the only safe approach.

A substance gets nominated for the 503A bulks list. FDA reviews it and may put it in front of the advisory committee. The committee hears the evidence and votes a recommendation, which is where MOTS-cis now — and that recommendation is non-binding. FDA then decides whether to act, and if it does, it must run formal rulemaking: a proposed rule, a public comment period, and a final rule. Only at the end of that does a substance actually appear on the list. Not one rung of that ladder is FDA approval.

A recommendation to add a substance to the 503A bulks list is a decision about pharmacy compounding eligibility. It is not FDA approval, which is a separate pathway in which a sponsor submits clinical evidence for a specific finished product.

It is also worth being precise about what this vote was not. These substances came off FDA’s 503A Category 2 list — the “significant safety risk” designation — back in April 2026, when their nominations were withdrawn, and that did not move them to Category 1. The July vote was a separate, later step: a recommendation to add them to a permission list. Coming off a restriction list in April and being recommended for a permission list in July are two different actions, months apart, and merging them into a single “ban lifted” story misstates both. The full sequence is on our FDA peptide compounding status page, and what has to happen next is laid out separately.

Nothing today. If a clinic or an online seller tells you the FDA just approved MOTS-c, or that it is newly legal and you should act before the window closes, that is a sales pitch resting on a misreading of a procedural vote. The rules governing what a pharmacy may compound are the same this week as last week. You can check one piece of that yourself in about ten seconds: FDA’s own 503A category list still carries its May 14, 2026 update date, because these votes did not change it.

Anything sold to you in the meantime as “research use only” is not a prescription, is not dispensed by a licensed pharmacy, and carries no guarantee about what is actually in it. Given that FDA’s own chemists told the committee they could not always say what these compounds are, that is not an abstract concern. If you want the clinical picture for this substance rather than the regulatory one, see the MOTS-c overview; for state law, see is peptide therapy legal in Nevada.